Rocket Pharmaceuticals, Inc. is a US-based pharmaceutical company with a medium-risk ESG score of 29.1. Specializing in gene therapies for rare pediatric diseases, Rocket Pharmaceuticals is dedicated to developing treatments for conditions such as Danaon Disease, Fanconi Anemia, Leukocyte Adhesion, Pyruvate Kinase Deficiency, and Infantile Malignant Osteopetrosis.